Fulford (India) Peer Comparison

NSE: FULFORD | BSE: 506803

₹2,362.00

₹1.00 (0.04%)

As on 30-Jul-2015IST

Market cap

₹921 Cr

Revenue (TTM)

₹109 Cr

P/E Ratio

32.5

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	921	31,680	25,868	25,655	24,429
Revenue (₹ Cr)	109	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	28.33	414.00	-371.81	387.35	288.22
Net Margin (%)	23.93	11.23	-3.93	26.01	14.79
RoE (%)	13.36	8.38	-3.85	25.18	29.77
Price to Earnings	32.51	77.46	--	66.42	84.76
Price-To-Book	6.15	6.29	3.23	14.87	18.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	109.36	2,843.99	--	239.64	263.02
Total Income	118.42	2,904.07	--	242.49	281.09
Total Expenditure	79.28	2,746.23	--	198.63	182.42
EBITDA	30.07	97.76	--	41.02	80.60
Depreciation	0.09	224.14	--	3.52	18.45
EBIT	29.99	-126.38	--	37.50	62.15
Interest	0.29	275.74	--	5.59	6.20
Other Income	9.06	60.08	--	2.84	18.07
Exceptional Items	--	--	--	--	--
Profit before Tax	38.76	-342.04	--	34.75	74.01
Provision for Tax	10.43	-204.09	--	7.28	24.60
Profit after Tax	28.33	-137.95	--	27.47	49.41

Liabilities (₹ Cr)

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	225.93	2,671.67	--	111.81	340.50
Minority Interest	--	385.79	--	--	--
Non-Current Liabilities	-2.88	1,194.85	--	25.46	9.30
Current Liabilities	26.61	3,497.18	--	94.61	77.54
Total Liabilities	254.91	8,147.66	--	231.89	430.39

Assets (₹ Cr)

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	78.87	5,319.66	--	104.93	162.50
Current Assets	170.80	2,400.54	--	121.04	264.84
Total Assets	254.91	8,147.66	--	231.89	430.39
Total Debt*	0.00	3,213.23	--	59.42	30.27
Net Current Assets	144.19	-1,096.64	--	26.42	187.31
Contingent Liabilities	143.54	641.08	--	0.07	46.45

Cashflow (₹ Cr)

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	3.65	648.96	--	27.08	5.47
Cash Flow from Investing Activities	69.78	-155.53	--	-23.94	-84.34
Cash from Financing Activities	-0.77	-679.58	--	0.19	80.07
Net Cash Inflow / Outflow	72.66	-186.15	--	3.33	1.21

Ratios

Profitability Ratios

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	18.42	-1.11	--	27.09	26.00
ROE (%)	13.36	-5.22	--	29.78	18.67
ROA (%)	12.02	-1.80	--	12.34	13.65
EBIT Margin (%)	35.79	5.55	--	18.30	37.51
Net Margin (%)	23.93	-4.75	--	11.33	17.58
Cash Profit Margin (%)	25.99	3.03	--	12.93	25.80

Growth Ratios

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	9.65	-20.24	--	0.47	71.02
EBIT Growth (%)	-2.31	1,004.01	--	3.29	159.60
Net Profit Growth (%)	1.95	55.76	--	17.92	168.16
EPS Growth (%)	1.95	64.44	--	17.92	148.52
Book Value Growth (%)	14.07	-0.03	--	34.77	68.83

Valuation Ratios

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	0.00	--	0.00	0.00
Price / Book Value	0.00	0.72	--	0.00	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-3.40	30.78	--	1.51	0.00
Market Cap (₹ Cr)	0.00	1,913.03	--	0.00	0.00

Solvency Ratios

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.00	1.22	--	0.56	0.09
Short term debt to equity ratio	--	0.34	--	0.30	0.06
Current Ratio	6.42	0.69	--	1.28	3.42
Quick Ratio	6.34	0.48	--	0.73	2.93
Interest Coverage	134.58	-0.24	--	7.22	12.93

Operating Efficiency Ratios

	Fulford (India)	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	16.09	43.70	--	23.54	53.26
Asset Turnover	0.46	0.37	--	1.08	0.73
Receivable days	34.64	161.49	--	100.90	155.79
Inventory Days	23.56	98.54	--	69.31	39.61
Payable days	176.33	263.19	--	169.65	159.03
Cash Conversion Cycle	-118.13	-3.16	--	0.56	36.37